Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
PCVX

PCVX - Vaxcyte, Inc. Stock Price, Fair Value and News

$51.37-2.98 (-5.48%)
Market Closed

26/100

PCVX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

26/100

PCVX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$42.18

Target 3M

$48.25

Target 6M

$44.82

PCVX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PCVX Price Action

Last 7 days

2.3%

Last 30 days

10.3%

Last 90 days

14.8%

Trailing 12 Months

-44.2%

PCVX RSI Chart

PCVX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PCVX Valuation

Market Cap

6.7B

Price/Earnings (Trailing)

-10.23

Price/Sales (Trailing)

2.3K

Price/Free Cashflow

-12.07

PCVX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$42.18

Target 3M

$48.25

Target 6M

$44.82

PCVX Fundamentals

PCVX Revenue

Revenue (TTM)

2.3M

PCVX Earnings

Earnings (TTM)

-657.2M

Earnings Growth (Yr)

-106.38%

Earnings Growth (Qtr)

-27.77%

PCVX Profitability

Return on Equity

-22.72%

Return on Assets

-20.72%

Free Cashflow Yield

-8.29%

PCVX Investor Care

Shares Dilution (1Y)

5.03%

Diluted EPS (TTM)

-4.84

PCVX Alerts

  • 2 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202404.5M2.3M0
20232.4M4.2M5.7M4.8M
20221.7M2.1M1.9M1.9M
202102.5M1.8M1.9M
2020797.3K1.4M1.9M2.5M
2019000237.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Vaxcyte, Inc.

PCVX
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
 CEO
 WEBSITEhttps://vaxcyte.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES158

Vaxcyte, Inc. Frequently Asked Questions

PCVX is the stock ticker symbol of Vaxcyte, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Vaxcyte, Inc. is 6.72 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check PCVX's fair value in chart for subscribers.

The fair value guage provides a quick view whether PCVX is over valued or under valued. Whether Vaxcyte, Inc. is cheap or expensive depends on the assumptions which impact Vaxcyte, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PCVX.

As of Wed Jan 28 2026, PCVX's PE ratio (Price to Earnings) is -10.23 and Price to Sales (PS) ratio is 2.32 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PCVX PE ratio will change depending on the future growth rate expectations of investors.